Literature DB >> 8189225

Epidermal growth factor and basic fibroblast growth factor have independent actions on mesencephalic dopamine neurons in culture.

D Casper1, G J Roboz, M Blum.   

Abstract

Epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) are both trophic for dopamine neurons in cultures of dissociated embryonic rat mesencephalon, but the significance of this apparent overlap in neurotrophic activity is not yet known. In this study, we investigated the mechanisms of action of these two growth factors and the potential relationship between them. Using a nuclease protection assay, we determined that bFGF mRNA was expressed in the cultures. Double-label immunocytochemistry revealed that bFGF immunoreactive material could be detected in tyrosine hydroxylase immunoreactive neurons and glial fibrillary acidic protein immunoreactive astrocytes. EGF treatment increased bFGF mRNA content per culture dish. As we have previously demonstrated that EGF exerts its dopaminergic neurotrophic activity via an intermediate cell type, studies were designed to address whether the pathway by which EGF acts on dopaminergic neurons is mediated by the release of bFGF. However, the trophic action of EGF on dopamine neurons, represented by high-affinity neuronal dopamine uptake, could not be blocked by immunoneutralization of bFGF, suggesting that the actions of EGF were not mediated by bFGF release. The time course of the effects of EGF and bFGF on dopamine uptake were similar, with significant increases detectable only after 5 days in culture. Both growth factors were active in the picomolar-to-nanomolar range with maximal trophic activity between 0.4 and 2.5 nM. EGF, however, was the more potent mitogen under these conditions. When cultures were simultaneously incubated with maximal concentrations of EGF and bFGF, the effect on dopamine uptake was significantly greater than with either growth factor alone and, in fact, approximated the sum of the individual effects. On the basis of these results we conclude that these growth factors have independent effects on dopamine neurons of the mesencephalon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8189225     DOI: 10.1046/j.1471-4159.1994.62062166.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Wnt5a-dopamine D2 receptor interactions regulate dopamine neuron development via extracellular signal-regulated kinase (ERK) activation.

Authors:  Sehyoun Yoon; Mi-hyun Choi; Min Seok Chang; Ja-Hyun Baik
Journal:  J Biol Chem       Date:  2011-03-15       Impact factor: 5.157

2.  Astroglial-conditioned media and growth factors modulate proliferation and differentiation of astrocytes in primary culture.

Authors:  Vincenzo Bramanti; Agata Campisi; Daniele Tomassoni; Antonino Costa; Alfredo Fisichella; Venera Mazzone; Luca Denaro; Marcello Avitabile; Francesco Amenta; Roberto Avola
Journal:  Neurochem Res       Date:  2006-12-07       Impact factor: 3.996

3.  ErbB1 receptor ligands attenuate the expression of synaptic scaffolding proteins, GRIP1 and SAP97, in developing neocortex.

Authors:  D Yokomaku; H Jourdi; A Kakita; T Nagano; H Takahashi; N Takei; H Nawa
Journal:  Neuroscience       Date:  2005-10-14       Impact factor: 3.590

4.  Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein.

Authors:  Moonhee Lee; Yunhee Kang; Kyoungho Suk; Claudia Schwab; Sheng Yu; Patrick L McGeer
Journal:  J Biol Chem       Date:  2011-10-11       Impact factor: 5.157

Review 5.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

6.  Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease.

Authors:  Richard J E Armstrong; Pamela Tyers; Meena Jain; Andrew Richards; Stephen B Dunnett; Anne E Rosser; Roger A Barker
Journal:  Exp Brain Res       Date:  2003-06-03       Impact factor: 1.972

Review 7.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

Review 8.  Epidermal Growth Factor in the CNS: A Beguiling Journey from Integrated Cell Biology to Multiple Sclerosis. An Extensive Translational Overview.

Authors:  Giuseppe Scalabrino
Journal:  Cell Mol Neurobiol       Date:  2020-11-05       Impact factor: 5.046

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.